Breaking News Instant updates and real-time market news.

MRK

Merck

$62.51

-0.04 (-0.06%)

10:15
04/21/17
04/21
10:15
04/21/17
10:15

Observations at VA shows Merck's Zepatier has high SVR for HCV

Merck announced the presentation of findings from a retrospective database analysis of patients with chronic hepatitis C virus, HCV, infection who were administered ZEPATIER in the U.S. Department of Veterans Affairs, VA, healthcare system. For the evaluable population, 95.6% of veterans treated with ZEPATIER achieved the primary outcome of sustained virologic response, SVR, defined as undetectable HCV RNA at least twelve weeks after the end of treatment. For patients with no HCV RNA measurements at or after 12 weeks, the analysis used HCV RNA measurements available at least four and less than 12 weeks after the end of treatment. The response rates in the real-world setting of the VA supplement the overall findings from the controlled clinical studies of ZEPATIER. These findings will be presented today in an oral session at The International Liver Congress 2017 being held in Amsterdam, the Netherlands. Analysis of data from real-world medical settings can provide useful insights to supplement knowledge gained from randomized clinical trials," said Susan Shiff, senior vice president, center for observational and real-world evidence, Merck. "These data from a real-world VA setting add to the body of evidence on ZEPATIER and help deepen scientific understanding of the treatment of this complex disease affecting diverse, sometimes difficult to treat, patient populations."

  • 22

    Apr

  • 02

    May

  • 03

    May

  • 07

    May

  • 10

    May

  • 27

    May

  • 09

    Jun

  • 14

    Jun

MRK Merck
$62.51

-0.04 (-0.06%)

04/03/17
JPMS
04/03/17
NO CHANGE
JPMS
Overweight
Incyte trial news 'another clear positive,' says JPMorgan
JPMorgan analyst Cory Kasimov views the announcement of epacadostat and nivolumab combo moving into Phase 3 studies in first-line non-small cell lung cancer as well as first-line head and neck cancer in 2017 as "another clear positive" for Incyte (INCY). The stock in early trading is up 5% to $140.73. The news expands the breadth of the epacadostat combinations beyond just Merck (MRK) and could ease fears that Bristol-Myers (BMY) is only focused on its internal molecule, Kasimov tells investors in a research note. The analyst continues to be encouraged by Incyte's progress in immuno-oncology and keeps an Overweight rating on the shares.
04/04/17
RBCM
04/04/17
NO CHANGE
RBCM
Incyte price target raised to $157 from $138 at RBC Capital
RBC Capital analyst Simos Simeonidis raised his price target on Incyte (INCY) after Incyte and Bristol-Myers (BMY) announced that they would conduct Phase III trials of the combination of Incyte's epacadostat and Bristol-Myers' Opdivo in 1L lung and head-and-neck cancer. The analyst notes that Merck last week made a similar announcement regarding the use of epacadostat and Merck's Keutruda in additional Phase III trials. Simeonidis keeps an Outperform rating on Incyte.
04/04/17
STFL
04/04/17
NO CHANGE
STFL
NewLink Genetics should be bought on weakness after data, says Stifel
Stifel analyst Stephen Willey said NewLink Genetics' (NLNK) combination of indoximod and Merck's (MRK) pembrolizumab in patients with treatment-naive melanoma demonstrated an overall response rate, or ORR, that is "essentially identical" to the previously-reported results from the Incyte (INCY)-Merck study of epacadostat/pembrolizumab. The lower rate of complete responses he doesn't "find terribly surprising" given what is already known about the current indoximod formulation, he tells investors. Willey, who views today's weakness as an interesting buying opportunity ahead of P1/2 data on the atezolizumab + GDC-0919 combination, keeps a Buy rating on Newlink shares.
04/20/17
JEFF
04/20/17
NO CHANGE
Target $51
JEFF
Underperform
Jefferies lowers Merck estimates, drops target to $51
Jefferies analyst Jeffrey Holford lowered his earnings estimates for Merck by up to 3% citing concerns on pricing for Januvia/Janumet. The analyst notes that his mid-term estimates are now up to 11% below consensus. Holford expects Keytruda, Januvia and Gardasil to miss expectations Q1. He cut his price target for Merck to $51 from $52 and keeps an Underperform rating on the name.

TODAY'S FREE FLY STORIES

CCL

Carnival

$68.56

-0.46 (-0.67%)

05:22
01/22/18
01/22
05:22
01/22/18
05:22
Periodicals
Woman falls to death from balcony aboard Carnival ship, Miami Herald reports »

A woman aboard the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EQM

EQT Midstream Partners

$76.51

0.17 (0.22%)

, EQGP

EQT GP

$28.44

-0.19 (-0.66%)

05:21
01/22/18
01/22
05:21
01/22/18
05:21
Downgrade
EQT Midstream Partners, EQT GP, Rice Midstream rating change  »

EQT Midstream Partners…

EQM

EQT Midstream Partners

$76.51

0.17 (0.22%)

EQGP

EQT GP

$28.44

-0.19 (-0.66%)

RMP

Rice Midstream

$22.20

0.05 (0.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EQGP

EQT GP

$28.44

-0.19 (-0.66%)

05:19
01/22/18
01/22
05:19
01/22/18
05:19
Initiation
EQT GP initiated  »

EQT GP resumed with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EQT

EQT Corporation

$56.03

-1.12 (-1.96%)

05:18
01/22/18
01/22
05:18
01/22/18
05:18
Initiation
EQT Corporation initiated  »

EQT Corporation resumed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ANDX

Andeavor Logistics

$52.52

0.12 (0.23%)

05:16
01/22/18
01/22
05:16
01/22/18
05:16
Initiation
Andeavor Logistics initiated  »

Andeavor Logistics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Feb

ANDV

Andeavor

$118.35

0.14 (0.12%)

05:15
01/22/18
01/22
05:15
01/22/18
05:15
Initiation
Andeavor initiated  »

Andeavor resumed with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Feb

IPAR

Inter Parfums

$47.80

0.9 (1.92%)

05:13
01/22/18
01/22
05:13
01/22/18
05:13
Downgrade
Inter Parfums rating change  »

Inter Parfums downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

X

U.S. Steel

$38.77

-0.26 (-0.67%)

, STLD

Steel Dynamics

$46.42

0.16 (0.35%)

05:11
01/22/18
01/22
05:11
01/22/18
05:11
Upgrade
U.S. Steel, Steel Dynamics, Nucor, Commercial Metals rating change  »

U.S. Steel upgraded to…

X

U.S. Steel

$38.77

-0.26 (-0.67%)

STLD

Steel Dynamics

$46.42

0.16 (0.35%)

NUE

Nucor

$68.72

-0.1 (-0.15%)

CMC

Commercial Metals

$24.82

-0.27 (-1.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 30

    Jan

  • 01

    Feb

ESPR

Esperion

$77.20

2.24 (2.99%)

05:06
01/22/18
01/22
05:06
01/22/18
05:06
Downgrade
Esperion rating change  »

Esperion downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VRX

Valeant

$21.52

-0.58 (-2.62%)

05:02
01/22/18
01/22
05:02
01/22/18
05:02
Recommendations
Valeant analyst commentary  »

Valeant selloff Friday…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Feb

  • 18

    Jun

  • 27

    Aug

WP

Worldpay

$78.73

-0.35 (-0.44%)

04:57
01/22/18
01/22
04:57
01/22/18
04:57
Recommendations
Worldpay analyst commentary  »

Worldpay price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QDEL

Quidel

$46.93

0.46 (0.99%)

, QGEN

Qiagen

$32.87

0.31 (0.95%)

04:55
01/22/18
01/22
04:55
01/22/18
04:55
Recommendations
Quidel, Qiagen analyst commentary  »

Quidel price target…

QDEL

Quidel

$46.93

0.46 (0.99%)

QGEN

Qiagen

$32.87

0.31 (0.95%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MCO

Moody's

$159.18

1.6 (1.02%)

04:55
01/22/18
01/22
04:55
01/22/18
04:55
Conference/Events
Moody's management to meet with RBC Capital »

RBC Capital Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 09

    Feb

04:55
01/22/18
01/22
04:55
01/22/18
04:55
General news
Breaking General news story  »

4-Week Bill Announcement…

AKTX

Akari Therapeutics

$3.59

-0.01 (-0.28%)

04:55
01/22/18
01/22
04:55
01/22/18
04:55
Conference/Events
Akari Therapeutics management to meet with William Blair »

Group luncheon to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

SANM

Sanmina

$35.45

0.5 (1.43%)

04:55
01/22/18
01/22
04:55
01/22/18
04:55
Conference/Events
Sanmina to hold a conference call »

Management holds an…Webcast Link

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 29

    Jan

04:55
01/22/18
01/22
04:55
01/22/18
04:55
General news
Breaking General news story  »

6-Month Bill Auction to…

JAGX

Jaguar Health

$0.16

-0.0169 (-9.83%)

04:55
01/22/18
01/22
04:55
01/22/18
04:55
Conference/Events
Jaguar Health to hold a conference call »

Management provides an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

FE

FirstEnergy

$29.40

-0.16 (-0.54%)

04:55
01/22/18
01/22
04:55
01/22/18
04:55
Conference/Events
FirstEnergy participates in a webcast with Wolfe Research »

Utilities Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

04:55
01/22/18
01/22
04:55
01/22/18
04:55
Conference/Events
UBS REITs analyst holds an analyst/industry conference call »

REITs Analyst Yulico…

LLEX

Lilis Energy

$4.99

-0.12 (-2.35%)

04:55
01/22/18
01/22
04:55
01/22/18
04:55
Conference/Events
Lilis Energy management to meet with Seaport Global »

Meetings to be held on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 23

    Jan

  • 24

    Jan

  • 30

    Jan

  • 31

    Jan

NAVG

Navigators

$49.65

0.4 (0.81%)

04:55
01/22/18
01/22
04:55
01/22/18
04:55
Conference/Events
Navigators management to meet with William Blair »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 16

    Feb

PETS

PetMed Express

$53.24

2.67 (5.28%)

04:55
01/22/18
01/22
04:55
01/22/18
04:55
Technical Analysis
Technical Earnings Preview: PetMed Express at life highs before news »

The stock is at life…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

04:55
01/22/18
01/22
04:55
01/22/18
04:55
General news
Chicago Fed National Activity Index Level to be reported at 08:30 »

December Chicago Fed…

BNED

Barnes & Noble Education

$7.70

0.25 (3.36%)

04:55
01/22/18
01/22
04:55
01/22/18
04:55
Conference/Events
Barnes & Noble Education management to meet with Sidoti »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 23

    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.